The FINANCIAL — Merck on June 13 announced results from two Phase 3 studies evaluating MK-1293, Merck’s investigational, follow-on biologic insulin glargine candidate for the treatment of people with ...

Sanofi’s Lantus, its most commonly prescribed insulin, will sell for $35 a month through GoodRx Holdings Inc. in a deal that signals the drug-discount site’s growing business with large pharma ...

The FDA approved Semglee (insulin glargine-yfgn) as the first interchangeable biosimilar insulin product for diabetes, allowing for pharmacy-level substitution in states that allow it, the agency ...

Civica plans to distribute its insulin glargine to pharmacies across the United States for $45 for a box of five pens. “Through the partnership we formed with Civica more than six years ago, BCBSA and ...

Insulin remains one of the most important treatments for people living with diabetes. Whether someone has Type 1 diabetes or advanced Type 2 diabetes, insulin therapy helps control blood sugar levels, ...